Nasdaq:US$9.78 (+0.20) | HKEX:HK$16.36 (-0.66) | AIM:£1.56 (-0.03)

About this report

This is the first standalone sustainability report published by HUTCHMED (China) Limited (“HUTCHMED” or the “Company”). It was prepared on an entirely voluntary basis and showcases our commitment to sustainable development and highlights our environmental, social and governance (“ESG”) manage­ment approaches over material topics relating to the operations of our two segments: (1) Oncology/­Immunology and (2) Other Ventures.

The report does not include details of our corporate governance principles, which are contained in the Corporate Governance Report within our 2020 Annual Report.

2020 Sustainability Report
HUTCHMED 2020 Sustainability Report

View Report

HUTCHMED’s material topics

  • Business ethics, including staff and partner awareness
  • Drug research-related topics, including animal welfare and intellectual property
  • Drug development-related topics, including clinical trial safety and personal data privacy and security
  • Commercial operations responsibilities, including quality, safety and traceability; patient monitoring and reporting; responsible marketing; and fair access of drugs
  • Environmental topics including waste and emissions
  • Management of our people, including talent acquisition, retention, development and engagement; occupational health and safety; and community investment.

Sustainable Development Goals

Our actions support the following United Nations Sustainable Development Goals: